Show simple item record

dc.contributor.authorVishwanathan, K
dc.contributor.authorDickinson, P
dc.contributor.authorSo, K
dc.contributor.authorThomas, K
dc.contributor.authorChen, Y
dc.contributor.authorde Castro Carpeno, J
dc.contributor.authorDingemans, A
dc.contributor.authorKim, H
dc.contributor.authorKim, J
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorYang, J
dc.contributor.authorBui, K
dc.contributor.authorWeilert, D
dc.contributor.authorHarvey, R
dc.date.accessioned2018-03-17T21:24:17Z
dc.date.available2018-03-17T21:24:17Z
dc.date.issued2018-01-30
dc.identifier.citationThe effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. 2018, Br J Clin Pharmacolen
dc.identifier.issn1365-2125
dc.identifier.pmid29381826
dc.identifier.doi10.1111/bcp.13534
dc.identifier.urihttp://hdl.handle.net/10541/620849
dc.description.abstractWe investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor kinase inhibitor osimertinib, in patients with advanced non-small cell lung cancer in two phase I, open-label, two-part clinical studies. Part one of both studies is reported.
dc.language.isoenen
dc.rightsArchived with thanks to British journal of clinical pharmacologyen
dc.titleThe effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.en
dc.typeArticleen
dc.contributor.departmentQuantitative Clinical Pharmacology, AstraZeneca, Waltham, MA, USAen
dc.identifier.journalBritish Journal of Clinical Pharmacologyen
html.description.abstractWe investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor kinase inhibitor osimertinib, in patients with advanced non-small cell lung cancer in two phase I, open-label, two-part clinical studies. Part one of both studies is reported.


This item appears in the following Collection(s)

Show simple item record